A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S T | U | V | W | X | Y | Z

Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.

Key Word / Drug Name
Issue #: Page #

A

abametapir 5:12
ABP 798 2:12
Abrilada™ 1:8; 2:10,11
acne 5:12
actinic keratosis 5:8-9
Aczone® 2:10
adalimumab 1:8; 2:10,11; 4:12
afamelanotide 2:10
AGLE-102 5:12
Aklief® 1:8; 2:1-2
alopecia areata 3:10; 4:6-11
Amzeeq™ 1:8; 2:10
androgen receptor inhibitor 5:12
anesthetic (topical) 1:8
anti-aging 2:3-9,10
anti-cancer 2:10; 4:9,12; 5:5, 8-12
antineoplastic 5:12
antioxidants 2:3-9
anti-wrinkle 2:3-9,10
apical sodium-dependent bile acid transporter 1:8
apremilast 2:10
Arazlo™ 2:10,12
ART-12 4:12
atezolizumab 5:12
atopic dermatitis 1:8; 2-10; 3:10; 4:6-12
autoimmune disease 3:5-9; 4:8-9; 5:8-11
Avsola™ 1:8; 2:11; 3:10

B

baricitinib 3:10; 4:6-11
basal cell carcinoma 5:8-11,12
Behçet’s disease 2:10
belimumab 2:11
Benlysta® 2:11
betamethasone dipropionate 2:11; 5:12
biologic 1:8; 2:10,11; 3:1-4,10; 4:12; 5:12
biosimilar 1:8;2:10-12; 4:12
blistering disorder 5:12
BMS-986165 4:7
botulinumtoxin type A 2:10
BRAF kinase inhibitor 5:12
bullous pemphigoid 4:8-12; 5:8-11

C

calcipotriene 2:11; 5:12
carbon dioxide laser 4:2-3
CD-directed cytolytic antibody 2:10
celiac disease 5:1-7
cellulite 4:12
cetirizine hydrochloride 1:8; 2:11
chemoprevention 5:8-11
clascoterone 5:12
collagenase clostridium histolyticum 4:12
comorbidities 5:1-7
cortexolone 17α-propionate 5:12
corticosteroid 2:11; 5:12
Cotellic® 5:12
crisaborole 3:10
cryoglobulinemic vasculitis 3:5-9
cryotherapy 4:2
cyclophosphamide 3:7
cytotoxic agent 3:7

D

dapsone 2:10
dermal filler 2:10
dermatosis papulose nigra 4:1-5
diabetes 5:1-7
diet & skin aging 2:3-9
diode laser 4:2
doxycycline 5:11
Duobrii™ 2:11; 5:12
dupilumab 2:10; 4:12
Dupixent® 2:10; 4:12
dyslipidemia 5:3-4
dystrophic epidermolysis bullosa 5:12

E

eczema 1:8; 2:10; 3:10; 4:6-12
electrodessication 4:2
Enbrel® 2:11
Enstilar® 2:11
eosinophilic granulomatosis with polyangiitis 3:5-9
epithelial tumors 1:1-4
epithelioid sarcoma 2:10,12
ER-004 4:12
erbium-doped fractionated laser 4:1-5
erythropoietic protoporphyria 2:10
Eskata™ 1:1-4
etanercept 2:11
Eticovo™ 2:11
Eucrisa® 3:10
excision 4:1-2
extracellular matrix (ECM) 2:4; 5:12
extracellular vesicle therapy 5:12

F

filaggrin gene 1:5
filgotinib 4:7
foods impacting MMPs 2:3-9

G

gastrointestinal disease 5:5
gene therapy 5:12
genetic counseling 1:6
glucocorticoids 3:7
glycation 2:3-9
golimumab 5:12
graft-versus-host disease 2:10
granulomatosis with polyangiitis 2:10; 3:5-9
guselkukmab 4:12
gut microbiome 2:5,7

H

Hadlima™ 2:11
hair loss 3:10
halobetasol propionate 2:11
hedgehog pathway inhibitor 5:12
hidradenitis suppurativa 4:7,9
histamine-1 receptor antagonist 1:8; 2:11
HP40 1:1-4
Hulio® 4:12
Humira® 2:10,11
hyaluronic acid 2:10
hydrogen peroxide topical solution 1:1-4
hyperglycemia 2:5
hypertension 5:3-4

I

ichthyosis 1:5-7
immunoglobulin A vasculitis 3:5-9
immunotherapy 2:10; 5:12
infection 4:9
INCB54707 4:7
inflammation 2:3-9,10; 3:5-9
inflammatory bowel disease 5:1-7
infliximab 1:8; 2:11; 3:10
interleukin-12 5:12
interleukin-13 2:10
interleukin-23 2:11; 3:1-4; 4:12; 5:12
interleukin-4 2:10; 4:12
itacitinib 4:7

J

Jakafi® 2:10
jakinibs 4:6-11
Janus kinase (JAK) inhibitor 2:10; 3:10; 4:6-11
Jeuveau™ 2:10
Juvéderm Voluma® XC 2:10
Jynneos™ 2:11

K

keratinization disorder 1:5-7
Keytruda® 2:10; 4:12
Koselugo® 3:10; 4:12
KTP laser 4:1-5

L

laser 4:1-5
lebrikizumab 1:8
lice 5:12
lichen planus pilaris 4:9
lidocaine 1:8

M

malignancy 2:10; 4:9,12; 5:5
maralixibat 1:8
matrix metalloproteinase (MMP) 2:3-9
MEK 3:10; 4:12; 5:12
melanocortin 1 receptor agonist 2:10
melanoma 2:10; 4:12; 5:12
Merkel cell carcinoma 2:10
metabolic syndrome 5:1-7
methotrexate 1:8; 3:7
microbiome 4:12
microscopic polyangiitis 3:5-9
minocycline 1:8; 2:10; 4:12
mitogen-activated protein kinase 3:10; 4:12; 5:12
monkey pox vaccine 2:11
monoclonal antibody 1:8; 2:10,11; 3:1-4,10; 4:12

N

Nd:YAG laser 4:1-5
Netherton syndrome 4:12
neurofibromatosis type 1 3:10; 4:12
neurotoxin 2:10
niacinamide 5:8-11
nicotinamide 5:8-11
non-alcoholic fatty liver disease 5:3-4
non-melanoma skin cancer 5:8-11
nutrient supplementation 2:6-7
nutrition 2:3-9

O

obesity 5:1-7
Odomzo® 5:12
Olumiant® 3:10
Otezla® 2:10
oxidation 2:3-9

P

PD-1 inhibitor 2:10; 4:12; 5:12
pediatric psoriasis 5:1-7
pediculicide 5:12
pegylated interferon alpha 3:7
pembrolizumab 2:10; 4:12
PF-04965842 4:7
PF-06651600 4:7
PF-06700841 4:7
phototoxicity 2:10
picosecond laser 4:2
plasma exchange 3:7
Pliaglis® 1:8
polycystic ovarian syndrome 5:3
prabotulinumtoxinA 2:10
primary vasculiltis 3:5-9
programmed cell death 1 inhibitor 2:10; 4:12
protein replacement therapy 4:12
pruritus 1:8
psoriasis 1:8; 2:10,11; 3:1-4,10; 4:6-8,12; 5:1-7,12
psoriatic arthritis 1:8; 2:10,11; 3:10; 4:12; 5:1-7,12
psychiatric disturbances 5:4
pruritus 4:1-5

Q

Q-switched laser 4:3
quality of life 5:1-7
Quzyttir™ 1:8; 2:11
Qwo™ 4:12

R

Remicade® 1:8; 2:11; 3:10
Retinoic acid receptor gamma 1:8; 2:1-2
retinoid 1:6,8; 2:1-2,10-12; 5:12
risankizumab 2:11; 3:1-4
Rituxan® 2:10
rituximab 2:10,12; 3:7
rosacea 4:12
ruxolitinib 2:10; 4:6-11

S

Scenesse® 2:10
seborrheic keratosis 1:1-4
secondary vasculitis 3:6
selumetinib 3:10; 4:12
Simponi®Aria™ 5:12
skin aging 2:3-9
skin of color 4:1-5
Skyrizi™ 2:11
smallpox vaccine 2:11
small-vessel vasculitis (primary) 3:5-9
sonidegib 5:12
squamous cell carcinoma 4:12; 5:8-11
Staphylococcus epidermidis 4:12
Stelara® 5:12
systemic lupus erythematosus 2:11; 4:6-11

T

Taclonex® 2:11
tazarotene 2:10,11,12
tazemetostat 2:10,12
Tazverik™ 2:10,12
Tecentriq® 5:12
tetracaine 1:8
tetracycline 5:11
thromboembolism 4:9-10
TNF-alpha 1:8; 2:10,11; 3:10; 4:12; 5:12
tofacitinib 4:6-11
transepidermal water loss 1:5
Tremfya® 4:12
trifarotene 1:8; 2:1-2
truncal acne 2:1-2
tryptophan 5:8
tumor necrosis factor-alpha 1:8; 2:10,11; 3:10; 4:12; 5:12

U

ultraviolet radiation damage 2:7
upadacitinib 4:7
urticaria 1:8; 2:11
ustekinumab 5:12
uveitis 5:3

V

vaccine 2:11
vasculitides 3:5-9
vemurafenib 5:12
vitamin B3 5:8-11
vitamin D 2:11; 5:12
vitiligo 4:6-11

W

Winlevi® 5:12
Wynzora® 5:12

X

Xeglyze™ 5:12
X-linked hypohidrotic ectodermal dysplasia 4:12

Y

Z

Zelboraf® 5:12
Zilxi™ 4:12